Bookmark
Forward
QuickView for Bretylium (compound)
PubChem
| Name: | bretylium |
|---|---|
| PubChem Compound ID: | 18499 |
| Molecular formula: | C11H17Br2N |
| Molecular weight: | 323.067 g/mol |
| Synonyms: |
AMMONIUM, (o-BROMOBENZYL)ETHYLDIMETHYL-, BROMIDE; Ornido; 3170-72-7; Bretyllium; N-o-Bromobenzyl-N-ethyl-N,N-dimethylammonium bromide; Bretylium bromide; Ordil; Benzenemethanaminium, 2-bromo-N-ethyl-N,N-dimethyl-, bromide (9CI); 59-41-6
|
DrugBank
Identification
| Name: | bretylium |
|---|---|
| Name (isomeric): | DB01158 |
| Drug Type: | small molecule |
| Synonyms: |
Bretylum; Bretylium tosylate; Bretylium p-toluenesulfonate; Bretylate; Bretylium tolsylate
|
| Brand: | Bretylan, Ornid, Darenthin, Bretylol, Darentin |
| Category: | Adrenergic Antagonists, Anti-Arrhythmia Agents, Antihypertensive Agents |
| CAS number: | 59-41-6 |
Pharmacology
| Indication: | For use in the prophylaxis and therapy of ventricular fibrillation. Also used in the treatment of life-threatening ventricular arrhythmias, such as ventricular tachycardia, that have failed to respond to adequate doses of a first-line antiarrhythmic agent, such as lidocaine. |
|---|---|
| Pharmacology: | Bretylium is a bromobenzyl quaternary ammonium compound which selectively accumulates in sympathetic ganglia and their postganglionic adrenergic neurons where it inhibits norepinephrine release by depressing adrenergic nerve terminal excitability. Bretylium also suppresses ventricular fibrillation and ventricular arrhythmias. |
| Mechanism of Action: |
Bretylium inhibits norepinephrine release by depressing adrenergic nerve terminal excitability. The mechanisms of the antifibrillatory and antiarrhythmic actions of bretylium are not established. In efforts to define these mechanisms, the following electrophysiologic actions of bretylium have been demonstrated in animal experiments: increase in ven...
show more » |
| Biotransformation: | No metabolites have been identified following administration in man and laboratory animals. |
| Half Life: | The terminal half-life in four normal volunteers averaged 7.8±0.6 hours (range 6.9-8.1). During hemodialysis, this patient's arterial and venous bretylium concentrations declined rapidly, resulting in a half-life of 13 hours. |
| Toxicity: | Oral, mouse: LD50 = 400 mg/kg. In the presence of life-threatening arrhythmias, underdosing with bretylium probably presents a greater risk to the patient than potential overdosage. However, one case of accidental overdose has been reported in which a rapidly injected intravenous bolus of 30 mg/kg was given instead of an intended 10 mg/kg dose during an episode of ventricular tachycardia. Marked hypertension resulted, followed by protracted refractory hypotension. The patient expired 18 hours later in asystole, complicated by renal failure and aspiration pneumonitis. Bretylium serum levels were 8000 ng/mL. |
| Affected organisms: | Humans and other mammals |
Interactions
| Drug interaction: |
|
|---|
Targets
